Table 1 Baseline demographic, anthropometric and disease characteristics of study treatment groups
Omarigliptin N = 154 | Placebo N = 153 | |
|---|---|---|
Age, years | 57.2 ± 8.4 | 58.4 ± 9.4 |
Female, n (%) | 81 (52.6) | 79 (51.6) |
Race, n (%) | ||
White | 116 (75.3) | 110 (71.9) |
Asian | 28 (18.2) | 29 (19.0) |
Black | 8 (5.2) | 7 (4.6) |
Multi-racial | 2 (1.3) | 6 (3.9) |
Native Hawaiian or other Pacific Island | 0 (0.0) | 1 (0.7) |
Ethnicity, n (%) | ||
Not Hispanic or Latino | 134 (87.0) | 140 (91.5) |
Hispanic or Latino | 14 (9.1) | 5 (3.3) |
Not reported | 2 (1.3) | 3 (2.0) |
Body Weight, kg | 87.8 ± 18.3 | 85.4 ± 21.2 |
BMI, kg/m2 | 31.8 ± 6.2 | 30.6 ± 5.8 |
HbA1c, % | 8.5 ± 0.8 | 8.6 ± 0.8 |
FPGa, mmol/L | 10.1 ± 2.3 | 10.2 ± 2.3 |
Duration of type 2 diabetes, years | 9.8 ± 5.3 | 10.4 ± 5.5 |
SU status at screening | ||
Glimepiride | 103 (66.9) | 104 (68.0) |
SU other than glimepiride | 51 (33.1) | 49 (32.0) |